BioSpace News Archive

Federal entity, leading cancer research center, independent IRB join those who meet the ‘gold standard’

Advicent announced today it has launched NaviPlan® 19.3, enabling financial professionals to leverage a robust healthcare dataset to deliver more accurate healthcare cost projections

Generex Biotechnology Corporation has issued a shareholder alert regarding recent trading activity that has adversely affected the company and its shareholders.

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, announced today the Phase 2b trial of MIN-117 in adult patients suffering from moderate to severe major depressive disorder (MDD) and presenting with symptoms of anxious distress failed to meet its primary and key secondary endpoints.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at upcoming conferences

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended September 30, 2019.

Statement of Matthew L. Myers, President, Campaign for Tobacco-Free Kids

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering

Varian (NYSE: VAR) today announced its first quarter fiscal year 2020 earnings release date.

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a human bioavailability study of CMIO-OLNZ, a 7-day matrix transdermal delivery system of olanzapine for the treatment of poly ADP ribose polymerase (PARP) inhibitor induced nausea and vomiting (PIINV) (the “Study”).